Venture Studio Model

Our venture studio model optimally aligns drug development opportunities with financing and experimental execution to increase success rates and shorten timelines. 

Foundery I LP, our investment arm, is overseen by our founding team of storied drug developers and provides our studio with access to financial capital. We have fully functioning labs to evaluate, validate, and prioritize drug target candidates and develop IND-enabling drug packages that can be out-licensed or used to spin-out companies (NewCos). 

Collectively, we maximize the chance of new drug development opportunities achieving clinical proof-of-concept (POC) and minimize the time to obtain clinical POC data with the ultimate goal of bringing more groundbreaking therapies to patients.

Shared service model

Academic Partners

We are closely tied to one of the world’s leading immunology centers at the University of California, San Francisco (UCSF). We provide an alternative approach to the time-intensive, and demanding traditional technology transfer process. 

By streamlining license negotiations and working closely with academic partners, we ensure that the most promising drug targets are rapidly identified, validated, and positioned for clinical success.

Innovative R&D Team

We utilize cutting-edge R&D platforms and an early-kill strategy to quickly de-risk therapeutic candidates and develop first-in-class therapies with improved chances of therapeutic and commercial success.

Our laboratories employ a team of highly experienced, dedicated, and focused drug developers with expertise in leading programs, antibody engineering, protein science, immune systems biology, in vitro pharmacology, in vivo pharmacology, bioanalytics, and biomarkers. 

Contact Us

Interested in learning more? We're looking forward to hearing from you.